Sidoti Estimates Prenetics Global’s Q1 Earnings (NASDAQ:PRE)

Prenetics Global Limited (NASDAQ:PRE) – Investment analysts at Sidoti issued their Q1 2028 EPS estimates for shares of Prenetics Global in a report issued on Wednesday, July 15th. Sidoti analyst A. Hantman anticipates that the company will post earnings of $0.28 per share for the quarter. The consensus estimate for Prenetics Global’s current full-year earnings is ($1.26) per share. Sidoti also issued estimates for Prenetics Global’s Q2 2028 earnings at $0.44 EPS and FY2028 earnings at $2.13 EPS.

Other research analysts have also recently issued reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prenetics Global in a research report on Tuesday, April 21st. Benchmark lifted their target price on Prenetics Global from $30.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $34.25.

Prenetics Global Price Performance

PRE opened at $18.29 on Thursday. The company has a market capitalization of $308.55 million, a price-to-earnings ratio of -3.99 and a beta of 0.26. The business’s 50-day moving average price is $18.70 and its two-hundred day moving average price is $18.47. Prenetics Global has a 1 year low of $7.18 and a 1 year high of $23.63.

Prenetics Global (NASDAQ:PRE) last announced its earnings results on Wednesday, June 10th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.07). The company had revenue of $35.95 million during the quarter, compared to analyst estimates of $36.00 million. Prenetics Global had a negative return on equity of 20.33% and a negative net margin of 62.45%.

Institutional Investors Weigh In On Prenetics Global

Large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC grew its stake in shares of Prenetics Global by 85.1% in the first quarter. Renaissance Technologies LLC now owns 31,322 shares of the company’s stock valued at $605,000 after buying an additional 14,400 shares in the last quarter. State of Wyoming bought a new stake in Prenetics Global during the first quarter worth $48,000. Stevens Capital Partners lifted its stake in Prenetics Global by 54.6% in the first quarter. Stevens Capital Partners now owns 28,147 shares of the company’s stock valued at $544,000 after acquiring an additional 9,940 shares during the last quarter. Quadrature Capital Ltd acquired a new stake in Prenetics Global in the fourth quarter valued at $468,000. Finally, Millennium Management LLC bought a new position in shares of Prenetics Global in the 4th quarter valued at about $810,000. Institutional investors and hedge funds own 25.01% of the company’s stock.

Trending Headlines about Prenetics Global

Here are the key news stories impacting Prenetics Global this week:

• Positive Sentiment: Prenetics said its IM8 business secured $1 billion in non-dilutive financing, which could support growth without issuing new shares and signals strong outside confidence in the subsidiary’s outlook. Prenetics’ IM8 Secures $1 Billion Non-Dilutive Financing as Revenue Outlook Rises
• Positive Sentiment: Management also highlighted that PRE continues to exceed expectations and is receiving preferential financing, reinforcing the idea that the company may have better operating momentum than the market had assumed. PRE Continues to Exceed Expectations and Receive Preferential Financing
• Positive Sentiment: CEOs comments about using the financing to fuel IM8’s growth suggest the company has a clearer path to scaling a high-growth subsidiary, which can improve investor sentiment around future revenue expansion. Prenetics CEO on securing 1 billion funding to fuel subsidiary IM8’s growth
• Neutral Sentiment: Sidoti and other analysts maintained a generally constructive stance overall, with a consensus recommendation of “Moderate Buy,” but the reports mostly focused on model updates rather than a major new catalyst. Prenetics Global Limited (NASDAQ:PRE) Given Consensus Recommendation of Moderate Buy by Analysts
• Negative Sentiment: Sidoti cut earnings estimates for several periods, including 2026-2027 quarters and FY2027, which could weigh on the stock because it implies weaker near-term profitability than previously expected.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.